Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CytoDyn Inc.

Get SEC filing alerts via email and in your feed for CytoDyn Inc.

CYDY

CytoDyn Inc.

About CytoDyn Inc.

CytoDyn Inc. is a biotechnology company focused on developing innovative treatments, primarily through its monoclonal antibody leronlimab targeting CCR5. Its research targets cancer, HIV, COVID-19, and inflammatory diseases, emphasizing clinical trials and regulatory approval. The company aims to leverage its proprietary technology, patents, and strategic partnerships to bring targeted biologic therapies to global markets.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from CytoDyn Inc.

1
1
CytoDyn Inc. CytoDyn Reports Net Income Turnaround to $3.7 Million for Fiscal Year Ending May 31, 2025

Via official filing (AI summary) | 11 months ago | 0 comments